Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition - Smith - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
BACKGROUND
Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the ...
A just-published study provides new insight into creatine in the context of Alzheimers. For all the references/articles I cited, article is coming tomorrow!#...
OmegaXL is a powerful natural supplement shown in clinical research to support joint comfort and function? It contains more than 30 healthy fatty acids, including DHA and EPA. Give it a try, OmegaXL works!
Helium says Earth is Only ~6,000 Years Old?! - YouTube
In this fascinating interview, Del Tackett talks with geologist Dr. Andrew Snelling about helium retention in zircon crystals from New Mexico granite. While ...
Jesus gave 7 Critical Warnings to the Church in the Book of Revelation, and they are desperately needed for the present Last-Days Church. but some of the mai...
Trump Gave ULTIMATUM to ISRAEL: Enforcing DAN 9:27 Covenant? - YouTube
Trump just gave an ultimatum to Israel to agree to divide the Land of Israel in a two-state solution. Is this the enforcing of the Dan 9:27 Covenant? Is this...
Public Health Risks of PFAS-Related Immunotoxicity Are Real | Current Environmental Health Reports
Purpose of Review The discovery of per- and polyfluoroalkyl substances (PFAS) in the environment and humans worldwide has ignited scientific research, government inquiry, and public concern over numerous adverse health effects associated with PFAS exposure. In this review, we discuss the use of PFAS immunotoxicity data in regulatory and clinical decision-making contexts and question whether recent efforts adequately account for PFAS immunotoxicity in public health decision-making. Recent Findings Government and academic reviews confirm the strongest human evidence for PFAS immunotoxicity is reduced antibody production in response to vaccinations, particularly for tetanus and diphtheria. However, recent events, such as the economic analysis supporting the proposed national primary drinking water regulations and clinical monitoring recommendations, indicate a failure to adequately incorporate these data into regulatory and clinical decisions. Summary To be more protective of public health, we recommend using all relevant immunotoxicity data to inform current and future PFAS-related chemical risk assessment and regulation. Biological measures of immune system effects, such as reduced antibody levels in response to vaccination, should be used as valid and informative markers of health outcomes and risks associated with PFAS exposure. Routine toxicity testing should be expanded to include immunotoxicity evaluations in adult and developing organisms. In addition, clinical recommendations for PFAS-exposed individuals and communities should be revisited and strengthened to provide guidance on incorporating immune system monitoring and other actions that can be taken to protect against adverse health outcomes.
In this video, Dr. Nathan Bryan debunks the outdated belief that fats cause heart disease, emphasizing that fats are essential for brain function, cell membr...
Seizures and epilepsy (mechanism of disease) - YouTube
This is a flowchart on seizures and epilepsy, covering the etiology, pathophysiology, and manifestations. ADDITIONAL TAGS: Atonic seizure ("drop attack"):Non...
Epilepsy is a common neurological disorder of which seizures are a core symptom. Approximately one third of epileptic patients are resistant to antiepileptic drugs and therefore require alternative therapeutic options. Dietary and nutritional ...
Effects of nutritional interventions on BDNF concentrations in humans: a systematic review - PubMed
Objectives: Brain-derived neurotrophic factor (BDNF) plays an essential role in brain and metabolic health. The fact that higher concentrations are associated with improved cognitive performance has resulted in numerous intervention trials that aim at elevating BDNF levels. This systematic re …
Specific Bacterial Taxa and Their Metabolite, DHPS, May Be Linked to Gut Dyshomeostasis in Patients with Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis - PubMed
Background: Neurodegenerative diseases (NDDs) are multifactorial disorders frequently associated with gut dysbiosis, oxidative stress, and inflammation; however, the pathophysiological mechanisms remain poorly understood. Methods: Using untargeted mass spectrometry-based metabolomics a …
Whole Coffee Cherry Extract Improves Working Memory and Response Inhibition: Acute and Longitudinal Results from a Remote, Randomized, Double-Blind, Placebo-Controlled Clinical Trial - PubMed
Earlier laboratory-based evidence has suggested that polyphenol-rich, decaffeinated whole coffee cherry extract (CCE) supports improvements in acute and long-term cognitive performance. To better understand CCE's potential to promote cognitive processing, we conducted a first-of-its-kind remote clin …
! ! Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility? | Journal of Neurology
Following reports of low striatal dopamine content in Parkinson’s disease, levodopa was shown to rapidly reverse hypokinesis, establishing the model of disease as one of dopamine deficiency. Dopaminergic therapy became standard of care, yet it failed to reverse the disease, suggesting the understanding of disease was incomplete. The literature suggests the potential for toxicity of dopamine and its metabolites, perhaps more relevant given the recent evidence for elevated cytosolic dopamine levels in the dopaminergic neurons of people with Parkinson’s. To understand the relevance of these data, multiple investigations are reviewed that tested dopamine reduction therapy as an alternative to dopaminergic agents. The data from use of an inhibitor of dopamine synthesis in experimental models suggest that such an approach could reverse disease pathology, which suggests that cytosolic dopamine excess is a primary driver of disease. These data support clinical investigation of dopamine reduction therapy for Parkinson’s disease. Doing so will determine whether these experimental models are predictive and this treatment strategy is worth pursuing further. If clinical data are positive, it could warrant reconsideration of our disease model and treatment strategies, including a shift from dopaminergic to dopamine reduction treatment of the disease.
Right Brain Bio is developing a data-driven treatment for Parkinson's - one so revolutionary that it will transform disease understanding and treatment.
